Literature DB >> 16288217

Smad4 haploinsufficiency in mouse models for intestinal cancer.

P Alberici1, S Jagmohan-Changur, E De Pater, M Van Der Valk, R Smits, P Hohenstein, R Fodde.   

Abstract

The Smad4(+/E6sad) mouse carries a null mutation in the endogenous Smad4 gene resulting in serrated adenomas and mixed polyposis of the upper gastrointestinal (GI) tract with 100% penetrance. Here, we show by loss of heterozygosity (LOH) analysis and immunohistochemistry (IHC) that, although the majority of the tumors appear at 9 months of age, somatic loss of the wild-type Smad4 allele occurs only at later stages of tumor progression. Hence, haploinsufficiency underlies Smad4-driven tumor initiation in the GI tract. As both the Apc and Smad4 tumor suppressor genes map to mouse chromosome 18, we have bred Smad4(+/E6sad) with the Apc(+/1638N) model to generate two distinct compound heterozygous lines carrying both mutations either in cis (CAS) or in trans (TAS). Strikingly, both models show increased tumor multiplicities when compared with the single mutant littermates, although CAS mice are more severely affected and became moribund at only 5-6 weeks of age. Phenotypic and molecular analyses indicate that Smad4 haploinsufficiency is sufficient to significantly affect tumor initiation and progression both prior to and upon loss of Apc function. Moreover, complete loss of Smad4 strongly enhances Apc-driven tumor formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16288217     DOI: 10.1038/sj.onc.1209226

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human.

Authors:  Paola Alberici; Emma de Pater; Joana Cardoso; Mieke Bevelander; Lia Molenaar; Jos Jonkers; Riccardo Fodde
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Giving APCmin tumours a SPARC.

Authors:  Alex Gregorieff; Hans Clevers
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

3.  Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice.

Authors:  Jennifer Nancy Hahn; Vincent George Falck; Frank Robert Jirik
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

Review 4.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.

Authors:  Barbara Jung; Jonas J Staudacher; Daniel Beauchamp
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

5.  SMAD4 immunohistochemistry reflects genetic status in juvenile polyposis syndrome.

Authors:  Danielle Langeveld; W Arnout van Hattem; Wendy W J de Leng; Folkert H Morsink; Fiebo J W Ten Kate; Francis M Giardiello; G Johan A Offerhaus; Lodewijk A A Brosens
Journal:  Clin Cancer Res       Date:  2010-08-03       Impact factor: 12.531

6.  New Therapeutics Targeting Colon Cancer Stem Cells.

Authors:  Arun Thenappan; Ying Li; Kirti Shetty; Lynt Johnson; E P Reddy; Lopa Mishra
Journal:  Curr Colorectal Cancer Rep       Date:  2009-10-01

7.  Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.

Authors:  Qinghua Zeng; Sharbani Phukan; Yanfei Xu; Maureen Sadim; Diana S Rosman; Michael Pennison; Jie Liao; Guang-Yu Yang; Chiang-Ching Huang; Laura Valle; Antonio Di Cristofano; Albert de la Chapelle; Boris Pasche
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  A new stochastic and state space model of human colon cancer incorporating multiple pathways.

Authors:  Wai Y Tan; Xiao W Yan
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

Review 9.  More than two decades of Apc modeling in rodents.

Authors:  Maged Zeineldin; Kristi L Neufeld
Journal:  Biochim Biophys Acta       Date:  2013-01-17

Review 10.  Smad4-mediated TGF-beta signaling in tumorigenesis.

Authors:  Guan Yang; Xiao Yang
Journal:  Int J Biol Sci       Date:  2010-01-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.